NCT04989335 2023-11-28
Bisantrene Combination for Resistant AML
Sheba Medical Center
Phase 2 Unknown
Clinical Trials
12 trialsNCT04217278 2023-05-10
COSI
University of Birmingham
Phase 2/3 Unknown
NCT05665114 2023-01-03
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
Phase 1 Unknown
NCT04112589 2022-03-14
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
PETHEMA Foundation
Phase 1/2 Unknown
NCT04716114 2021-11-02
ALIVE
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Unknown
NCT03257241 2021-10-01
PALG-AML1/2016
Polish Adult Leukemia Group
Phase 3 Unknown
NCT05016063 2021-08-23
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04221971 2020-10-01
NK Cell Infusion for Patients With Acute Myeloid Leukemia
Peking University People's Hospital
Phase 1 Unknown
NCT02275663 2015-01-06
Azacytidine Plus FLAG for Relapsed or Refractory AML
King Fahad Medical City
Phase 2 Unknown
NCT02024308 2013-12-31
AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
Changhai Hospital
Phase 4 Unknown
NCT00887042 2012-03-26
Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML
The Korean Society of Pediatric Hematology Oncology
Phase 1/2 Unknown
NCT00529880 2007-09-27
Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML
Cooperative Study Group A for Hematology
Phase 2 Unknown